Invesco Biotechnology & Genome ETF (PBE)
- Previous Close
61.15 - Open
61.04 - Bid --
- Ask --
- Day's Range
60.79 - 61.41 - 52 Week Range
52.47 - 67.76 - Volume
5,327 - Avg. Volume
15,285 - Net Assets 245.86M
- NAV 61.12
- PE Ratio (TTM) 16.14
- Yield 0.06%
- YTD Daily Total Return -7.09%
- Beta (5Y Monthly) 0.81
- Expense Ratio (net) 0.58%
The fund generally will invest at least 90% of its total assets in securities that comprise the underlying index. The underlying index was composed of common stocks of U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.
Invesco
Fund Family
Health
Fund Category
245.86M
Net Assets
2005-06-23
Inception Date
Performance Overview: PBE
Trailing returns as of 4/23/2024. Category is Health.
People Also Watch
Holdings: PBE
Top 10 Holdings (46.40% of Total Assets)
Sector Weightings
Related ETF News
Research Reports: PBE
Analyst Report: Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel multiple sclerosis drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is copromoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with Sobi) were spun off as part of Bioverativ in 2017. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (post-partum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology-related fields.
RatingPrice TargetRMBS: Lowering target price to $59.00
RAMBUS INC has an Investment Rating of HOLD; a target price of $59.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetAnalyst Report: United Airlines Holdings Inc
Based in Chicago, United Airlines Holdings is a global airline that transports passengers and freight through both mainline and regional operations. With a market cap of about $13.6 billion, United Airlines is generally regarded as a large-cap value stock.
RatingPrice TargetAnalyst Report: American Water Works Company, Inc.
American Water Works is the largest investor-owned US water and wastewater utility, serving approximately 3.5 million customers in 16 states. It provides water and wastewater services to residential, commercial, and industrial customers and operates predominantly in regulated markets. The company's nonregulated business is water services for military bases, which operates under long-term contracts with regulated-like returns.
RatingPrice Target